Sorrento Therapeutics Inc. (NASDAQ: SRNE) is 6.52% higher on its value in year-to-date trading and has touched a low of $1.55 and a high of $19.39 in the current 52-week trading range. The SRNE stock was last observed hovering at around $7.44 in the last trading session, with the day’s loss setting it -0.17% off its average median price target of $25.50 for the next 12 months. It is also 75.77% off the consensus price target high of $30.00 offered by 2 analysts, but current levels are 65.38% higher than the price target low of $21.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $7.27, the stock is -0.70% and -0.04% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.26 million and changing -2.28% at the moment leaves the stock 4.21% off its SMA200. SRNE registered 76.89% gain for a year compared to 6-month gain of 10.49%. The firm has a 50-day simple moving average (SMA 50) of $7.51 and a 200-day simple moving average (SMA200) of $8.49.
The stock witnessed a -7.62% loss in the last 1 month and extending the period to 3 months gives it a -39.16%, and is 3.41% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.93% over the week and 7.45% over the month.
Sorrento Therapeutics Inc. (SRNE) has around 310 employees, a market worth around $1.90B and $41.50M in sales. Fwd P/E is 2.11. Distance from 52-week low is 369.03% and -62.51% from its 52-week high. The company has generated returns on investments over the last 12 months (-91.30%).
Sorrento Therapeutics Inc. (SRNE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Sorrento Therapeutics Inc. (SRNE) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Sorrento Therapeutics Inc. is expected to release its quarterly report on 05/11/2021 and quarterly earnings per share for the current quarter are estimated at $5.75 with sales reaching $2.01B over the same period.The EPS is expected to shrink by -14.80% this year, but quarterly earnings will post 6,387.80% year-over-year. Quarterly sales are estimated to grow 15,337.20% in year-over-year returns.
Sorrento Therapeutics Inc. (SRNE) Top Institutional Holders
267 institutions hold shares in Sorrento Therapeutics Inc. (SRNE), with 40.12M shares held by insiders accounting for 15.71% while institutional investors hold 33.19% of the company’s shares. The shares outstanding are 251.21M, and float is at 221.63M with Short Float at 31.12%. Institutions hold 27.97% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 15.02 million shares valued at $167.43 million. The investor’s holdings represent 5.71% of the SRNE Shares outstanding. As of Sep 29, 2020, the second largest holder is State Street Corporation with 11.71 million shares valued at $130.55 million to account for 4.45% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 11.1 million shares representing 4.22% and valued at over $123.79 million, while Cormorant Asset Management, LP holds 2.28% of the shares totaling 6.0 million with a market value of $66.9 million.
Sorrento Therapeutics Inc. (SRNE) Insider Activity
A total of 0 insider transactions have happened at Sorrento Therapeutics Inc. (SRNE) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Smith Robin L, the company’s Director. SEC filings show that Smith Robin L bought 40,000 shares of the company’s common stock on Mar 05 at a price of $2.27 per share for a total of $90896.0. Following the purchase, the insider now owns 60000.0 shares.
Sorrento Therapeutics Inc. (SRNE): Who are the competitors?
The company’s main competitors (and peers) include Exelixis Inc. (EXEL) that is trading 24.02% up over the past 12 months. Short interest in the company’s stock has risen 6.36% from the last report on Nov 29, 2020 to stand at a total of 68.91 million short shares sold with a short interest ratio of 5.1.